Hepatitis Forums
Fatty Liver Disease Main Forums => Nonalcoholic Steatohepatitis (NASH) => Topic started by: Hep Editors on May 12, 2017, 10:07:56 am
-
A retooled version of the non-alcoholic steatohepatitis (NASH) drug FGF19 improved liver health on numerous fronts in a recent trial, MedPage Today reports. Previous research had indicated that FGF19 may promote hepatocellular carcinoma (HCC, the most common form of liver cancer). The new version is known as NGM282.
The Phase II study included 82 people with NASH, mild to advanced fibrosis of the liver and a minimum absolute liver fat content of 8 percent. The partcipants were randomly assigned to receive either 3 milligrams or 6 mg of NGM282 daily for 12 weeks or a placebo.
Findings were presented at the 52nd International Liver Congress in Amsterdam.
Read more...
https://www.hepmag.com/article/modified-version-nash-drug-linked-cancer-now-shows-promise